LONDON, Dec 18 (Reuters) - Vectura said its partnerSandoz had received Danish approval for an inhaledlung drug that analysts widely believe to be a generic versionof GlaxoSmithKline's $8 billion-a-year blockbusterAdvair.
British pharmaceutical company Vectura said in a statementon Wednesday that Danish regulators had confirmed approval ofAirFluSal Forspiro, which was previously know as VR315. (Reporting by Paul Sandle; Editing by Ben Hirschler)